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Summary
BACKGROUND: Securing the adherence over time to
contraception by adolescent girls is a challenge. Until now
little was known about this topic in Switzerland. The aim
of our study was to determine contraceptive continuation
rates among adolescents in this country and assess pos-
sible predictive factors for discontinuation.
METHODS: A prospective observational cohort study of
12- to 19-year-old girls starting contraception was per-
formed. Patients were interviewed again after 1 year by
phone, email or postal mail.
RESULTS: A total of 204 patients were included, of whom
85.8% chose a combined oestrogen-progestogen pill. The
answer rate 1 year later was 71%. Among these, continu-
ation of the initially prescribed contraceptive method was
observed in 73.1%. Factors statistically affecting the con-
tinuation rate were the initial contraceptive method, the
place of residence and sexual activity after 1 year. Clas-
sification of contraceptive methods in decreasing order of
continuation rate was the following: long acting reversible
contraception (LARC) methods, oestrogen-progestogen
pills, injections, progestogen pills, patches and rings. Ma-
jor reasons reported for stopping the prescribed contra-
ceptive method were ending sexual relations (54.3%), de-
veloping side effects (34.3%) or changing to another con-
traceptive method (22.9%). Neither age, nationality, smok-
ing, occupation, nor the legal representative’s knowledge
of the contraception influenced adherence.
CONCLUSION: Contraceptive continuation rate was high
among the adolescent population studied. The only pre-
dictive factor of discontinuation was the contraceptive
method. Our study also reveals that respecting teenagers’
confidentiality is essential as it does not negatively impact
the continuation rate. The significant impact of the type
of contraception on continuation rates stresses the impor-
tance of individualised counselling.
Key words: contraception, adolescent, medication adher-
ence, contraception behaviour, Switzerland
Introduction
Adolescence is a challenging step in life: teenagers face
anatomical and hormonal changes, alongside developing
their independence. Difficulty in self-projection into the
long-term future, as well as the need to break rules and
take risks, are part of this transition age. With the develop-
ment of a romantic and sexual life, contraception is need-
ed despite possible difficulties with adherence [1, 2]. A
large panel of contraceptive methods can now be suggest-
ed to teenagers: combined oestrogen-progestogen methods
(oral pill, vaginal ring or transdermal patch), progestogen-
only pills, trimestral injections of progestogen or long-act-
ing reversible contraception (LARC) methods including
subdermal progestogen implants and intra-uterine devices
(with progestogens or copper). Guaranteeing confidential-
ity from family or peers is crucial to allowing access to the
largest number of patients [3]. A successful doctor-patient
relationship participates in creating a trustworthy environ-
ment for prescription, thus increasing satisfaction and ad-
herence [3–7]. In Switzerland, the adolescent birth rate is
very low at 2.1/1000, as is adolescent abortion rate at 3.4/
1000 [8]. Among other factors that can explain these low
rates are education at school and easy access to health cen-
tres.
The literature shows great variations in continuation rates
depending on the studied population (country, parity, age,
socioeconomic status, etc.), and the methodology used to
measure continuation (number of follow-up visits, free
contraception, message reminders, etc.) [1, 9–22]. How-
ever, continuation seems to be influenced by the contra-
ceptive method, with decreasing rate from LARC, with a
79.8 to 100% continuation rate 1 year later, to oestrogen-
progestogen pills (12–72.7%), and finally to vaginal rings
and transdermal patches (0–31%) [1, 9, 10, 15, 20, 21].
Other identified factors known to have a negative impact
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on contraception continuation are smoking or school
dropout [11–14, 17, 23].
Currently there is growing evidence recommending the use
of LARC methods by adolescents, including as a first-line
method [9, 11, 24–28]. In Switzerland, the proportion of
adolescents who choose these contraceptive methods is un-
known.
As risks of unintended pregnancy increase with every
change of contraceptive method [1], we aimed to measure
continuity and factors that influence it. Thus, the primary
objective of our study was to determine contraceptive con-
tinuation rates among adolescents in Switzerland. Further
outcomes were to report the prescribed contraceptive
methods and to assess possible predictive factors of dis-
continuation.
Methods
Ethics approval
The Cantonal Ethic Committee of Human Research ap-
proved our study protocol on 24.01.2013. (Protocol 324/
12). The CHUV (Centre Hospitalier Universitaire Vaudois)
supported all financial costs; we received no private spon-
soring. The recruitment centres did not receive any com-
pensation for their work, nor did patients receive any com-
pensation for their participation.
Recruitment of subjects
We conducted a prospective observational cohort study
with an exploratory purpose and consecutively recruited
adolescent girls consulting in order to start contraception,
not necessarily for the first time in their lifetime. Recruit-
ment took place in the University Hospital of Lausanne
(adolescent gynaecology unit and a senior consultant’s
practice) and in seven sexual health centres, of which one
was also located in Lausanne and the other six in small and
middle-sized cities in the Canton of Vaud. The study be-
gan in March 2013 with the aim of including the conve-
nience sample of 200 patients. Inclusion criteria were: age
12 to 19 years and de novo prescription of a contracep-
tive method: combined oral contraception (COC), proges-
terone-only pill (PP), vaginal ring, transdermal patch, de-
pot medroxyprogesterone acetate (DMPA), LARC meth-
ods such as an intrauterine device (IUD) or a subdermal
etonorgestrel implant]. Exclusion criteria were: (1) meth-
ods prescribed for other indications than contraception
(such as COC for dysmenorrhoea or hormonal IUD for hy-
permenorrhoea), (2) contraceptive prescription already in
place, (3) suspicion of pregnancy, (4) desire for pregnancy
within a year, (5) lack of capacity of discernment, and (6)
poor comprehension of the French language.
Each participant signed a written informed consent form
and allowed the investigator to contact her 1 year later. It is
important to emphasise that in Switzerland adolescents can
receive contraception without informing their legal repre-
sentative; to respect this practical reality, informed consent
from the legal representative was not necessary for partici-
pation in the study.
Definitions
We wanted to measure the adherence to the method initial-
ly prescribed because our clinical experience shows that
risks of pregnancy increase not only in the case of con-
traception interruption but also upon contraceptive method
change. If an adolescent changes method, it is usually a
sign that the first prescribed contraception method was not
optimal from her point of view. That is why “discontin-
uers” were defined as patients who either did not use con-
traception anymore 1 year later, who had interrupted their
contraception for more than 4 weeks, or who had changed
contraceptive method.
Data
Upon inclusion, we recorded the following data: age, na-
tionality, gravidity and parity, prescribed contraceptive
method, number of sexual partners over the last month,
smoking, occupation, and place of residence (living alone,
at parents’ home, at partner’s home, or community centre).
We also recorded whether the legal representative knew
about the contraception or not, in order to measure the im-
pact of confidentiality on compliance. These data were also
recorded for patients who refused to participate, in order to
determine the representativeness of the included subjects
compared with those others who matched the selection cri-
teria.
One year later, we conducted a semi-structured interview
with each patient by telephone, email or postal mail, de-
pending on their preference. The questionnaire was in
French and is provided in appendix 1, available as a sepa-
rate file for downloading. To increase the reliability of an-
swers, contact was made by the principal investigator, who
did not take part in the screening of patients nor in their
follow-up. Questions focused on contraception continua-
tion, change of contraceptive method, satisfaction, forgot-
ten pills, noticed side effects, and patients’ opinion regard-
ing efficacy and price of their contraception and discretion
of their doctor. As some characteristics could have changed
during the year, we also repeated questions about sexual
partners, smoking, occupation, place of residence and the
legal representative’s knowledge of the contraception. Fi-
nally, we asked about pregnancies during the time of the
study. In order to measure their satisfaction, patients could
choose between “very unsatisfied”, “unsatisfied”, “neither
satisfied nor unsatisfied”, “satisfied” or “very satisfied”.
To avoid bias regarding adherence, we chose to contact
patients for one single interview instead of several times,
which could have artificially increased adherence. We nev-
ertheless asked if they had had follow-up visits in the
meantime.
Statistics
Associations between contraception continuation and its
potential predictive factors were assessed separately at the
time of inclusion into the study and 1 year later. Except for
age, all of the assessed predictive factors were categorical
variables. Therefore, their associations with contraception
continuation (continuers versus discontinuers) were esti-
mated and tested by means of contingency tables and Fish-
er’s exact tests. Age was compared between the continua-
tion and the discontinuation groups by means of a Student
t-test, after visual checking that the distribution was Gauss-
ian. The statistical package Stata, version 13 (StataCorp
LP, College Station, Texas) was used for the calculations.
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Results
Two hundred and four patients were included up to June
2014. In figure 1 we detail the distribution of patients from
the time of selection until the questionnaire 1 year later.
Only 7.3% of the patients who met the selection criteria re-
fused to participate in the study. These were more likely
to declare having no sexual relations at the time of recruit-
ment than those who accepted the study (60 vs 17.4%, p =
0.001 with Fisher’s exact test). This was the only signifi-
cant difference between the two groups.
The characteristics of the included patients are detailed in
table 1. In figure 2 we show the number of adolescent girls
per age group. Most COCs were second generation pills.
Smokers did not give preference to a method with a less-
er thromboembolic risk as they amounted to 42.9% of the
group using a method without oestrogen.
One year later, 71% of included patients answered the
questionnaire. The characteristics of the subjects lost to
follow-up are listed in table 2. The only significant differ-
ence was nationality; Swiss nationals answered more fre-
quently than non-Swiss after 1 year ater (75.2 vs 55.2% in
the lost to follow-up group, p value = 0.007).
The 1-year continuation rate was 73.1%. In table 3 we re-
port the characteristics of contraception continuers and dis-
continuers for each recorded variable. The factors that dif-
fered significantly between discontinuers and continuers
were: the contraceptive method prescribed at inclusion,
and sexual activity and place of residence 1 year later. Age,
nationality, smoking, occupation, sexual relations at the
time of inclusion, place of residence upon inclusion, and
the legal representative’s knowing about the contraception
were not significantly different between these two groups.
Continuation rates according to methods were: 0% for
patch and ring, 60% for PP, 75% for DMPA, 75.2% for
COC and 100% for LARC methods. Among patients who
Figure 1: Distribution of patients from recruitment to results.
continued contraception, 93.4% considered themselves
satisfied or very satisfied with their contraception. One out
of four agreed or totally agreed with the proposition “my
contraception is expensive”. Some continuers (16.7%)
agreed or totally agreed with the proposition “I often forgot
to take my contraception”. One fifth (19.8%) reported ad-
verse side effects, mostly irregular bleeding or mood
changes.
Among patients who chose LARC, two had an implant,
two a hormonal IUD and two a copper IUD. Four of the
six had informed their legal representative. One year after,
five of the six felt satisfied or very satisfied with their con-
traception, none complained about side effects, and none
Table 1: Characteristics of included patients.
Mean age in years 17.28 (range 14–19)
Nationality
Swiss 138 (69.35%)
Portuguese 19 (9.55%)
Other 42 (21.10%)
Unknown 5
Gravidity
0 203 (100%)
Unknown 1
Number of sexual partners
None 35 (17.41%)
One 159 (79.1%)
More than one 7 (3.48%)
Unknown 3
Smoking
Yes 77 (38.31%)
No 124 (61.69%)
Unknown 3
Activity
Studies (school, college, university) 124 (61.39%)
Apprenticeship 59 (29.21%)
Employee 7 (3.47%)
Without 12 (5.94%)
Unknown 2
Place of residence
Parents’ home 189 (93.56%)
Partner’s home 1 (0.5%)
Alone 4 (1.98%)
Community centre 6 (2.97%)
Other 2 (0.99%)
Unknown 2
Legal representative informed about
contraception
Yes 129 (65.15%)
No 69 (34.35%)
Unknown 6
Contraceptive method
COC 175 (85.78%)
PP 9 (4.41%)
Ring 5 (2.45%)
Patch 2 (0.98%)
DMPA 7 (3.43%)
Implant 2 (0.98%)
IUD 4 (1.96%)
COC = combined oral contraception; PP = progesterone-only pill; Ring
= vaginal ring; patch = transdermal patch; DMPA = depot medroxyprog-
esterone acetate; implant = subdermal etonorgestrel implant; IUD = in-
tra-uterine device Unknown factors were not included in the percent-
ages.
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Table 3: Comparison of continuers with discontinuers for each factor.
Total patients who answered
n = 145
Continuers
n = 106
Discontinuers
n = 39
p-value
At inclusion
Mean age (years) 17.27 17.36 17.03 0.215
Nationality 0.277
Swiss 106 (75.18%) 80 (77.67%) 26 (68.42%)
Non-Swiss 35 (24.82%) 23 (23.33%) 12 (31.58%)
Unknown 4 3 1
Method 0.011
COC 125 (86.21%) 94 (88.68%) 31 (79.49%)
PP 5 (3.45%) 3 (2.83%) 2 (5.13%)
Ring 4 (2.76%) 0 4 (10.26%)
Patch 1 (0.69%) 0 1 (2.56%)
DMPA 4 (2.76%) 3 (2.83%) 1 (2.56%)
Implant 2 (1.28%) 2 (1.89%) 0
IUD 4 (2.76%) 4 (3.77%) 0
Sexual partners 0.859
None 27 (19%) 21 (20.39%) 6 (15.38%)
One 110 (77.46%) 78 (75.73%) 32 (82.05%)
More than one 5 (3.52%) 4 (3.89%) 1 (2.56%)
Unknown 3 3 0
Activity 0.573
Studies 89 (62.24%) 67 (63.81%) 22 (57.89%)
Apprenticeship 43 (30.07%) 31 (29.52%) 12 (31.58%)
Working 5 (3.5%) 4 (3.81%) 1 (2.63%)
Without 6 (4.2%) 3 (2.86%) 3 (7.89%)
Unknown 2 1 1
Place of residence 0.416
Parents’ home 135 (94.41%) 101 (95.28%) 34 (91.89%)
Partner’s home 1 (0.7%) 1 (0.94%) 0
Alone 3 (2.1%) 1 (0.94%) 2 (5.41%)
Community centre 4 (2.8%) 3 (2.98%) 1 (2.7%)
Unknown 2 0 2
Smoking 0.330
Yes 54 (37.50%) 37 (34.91%) 17 (44.74%)
No 90 (62.50%) 69 (65.09%) 21 (55.26%)
Unknown 1 0 1
Legal representative informed 0.241
Yes 91 (64.54%) 69 (67.65%) 22 (56.41%)
No 50 (35.46%) 33 (32.35%) 17 (43.59%)
Unknown 4 4 0
Consultation 0.265
Family planning 124 (85.52%) 90 (84.91%) 34 (87.18%)
Adolescent unit 10 (6.9%) 6 (5.66%) 4 (10.26%)
Private practice 11 (7.59%) 10 (9.43%) 1 (2.56%)
One year after
Sexual partners 0.001
None 37 (25.69%) 20 (19.05%) 17 (43.59%)
One 104 (72.22%) 84 (80%) 20 (51.28%)
More than one 3 (2.08%) 1 (0.95%) 2 (5.13%)
Unknown 1 1 0
Activity 0.940
Studies 74 (51.03%) 55 (51.89%) 19 (48.72%)
Apprenticeship 56 (38.62%) 40 (37.74%) 16 (41.03%)
Working 9 (6.21%) 7 (6.6%) 2 (5.13%)
Without 6 (4.14%) 4 (3.77%) 2 (5.13%)
Place of residence 0.020
Parents’ home 119 (85.00%) 90 (87.38%) 29 (78.38%)
Partner’s home 6 (4.29%) 6 (5.83%) 0
Alone 6 (4.29%) 3 (2.91%) 3 (8.11%)
Community centre 4 (2.86%) 3 (2.91%) 1 (2.7%)
Other 5 (3.57%) 1 (0.97%) 4 (10.81%)
Unknown 5 3 2
Original article Swiss Med Wkly. 2017;147:w14504
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 4 of 8
agreed with the proposition “my contraception is expen-
sive”.
In the discontinuer group, various reasons for interruption
were reported: 54.3% no longer had sexual relations,
34.3% noticed adverse side effects, 22.9% had changed
contraceptive method, 22.9% often forgot to take their con-
traception, 20% found the contraception too expensive and
8.8% feared inefficacy of the method. The side effects re-
ported in this group were mostly weight gain, acne and
headaches.
Fifty-two percent of continuers and 44% of discontinuers
reported at least one follow-up visit during the study peri-
od.
Two patients reported a pregnancy during the study period.
Both pregnancies were unintended and terminated. These
patients initially had a COC prescription and changed after
the abortion, one choosing a patch, the other an IUD.
Discussion
The purpose of our study was to learn more about ado-
lescents’ long-term contraception use in Switzerland. Our
adolescent contraception continuation rate was 73.1%.
This is high compared with large prospective cohort Amer-
ican studies. Raine [1] found a continuation rate of 18.5%
and Rosenstock [9] 44% for non-LARC methods. Suhonen
[15] had a comparable continuation rate of 79.8% for hor-
monal IUD and 72.7% for COC in a prospective ran-
domised study of Scandinavian 18- to 25-year-old women.
In our study, we defined discontinuers as adolescents who
changed contraception or interrupted it transitorily before
resuming it. Therefore, if we consider all the adolescents in
our study who had contraception in place 1 year later, the
percentage is even higher at 86.2%. This high rate is a first
measurable explanation of the low level of teenage preg-
Figure 2: Number of adolescent girls per age group.
nancies in Switzerland. However, continuation rates varied
depending on the initial contraceptive method prescribed.
We did not find other predictive factors of discontinuation
in our study, but given our relatively small sample of pa-
tients, we might have insufficient power to detect some of
them.
Table 2: Characteristics of patients lost to follow-up.
Mean age (years) 17.35
Nationality
Swiss 32 (55.17%)
Other 26 (44.83%)
Unknown 1
Gravidity
0 59 (100%)
Number of sexual partners
None 8 (13.56%)
One 49 (83.05%)
More than one 2 (3.39%)
Smoking
Yes 23 (40.35%)
No 34 (59.65%)
Unknown 2
Activity
Studies (school, college, university) 35 (59.32%)
Apprenticeship 16(27.12%)
Employee 2 (3.39%)
Without 6 (10.17%)
Place of residence
Parents’ home 54 (91.53%)
Partner’s home 0
Alone 1 (1.69%)
Community centre 2 (3.39%)
Other 2 (3.39%)
Legal representative informed about
contraception
Yes 38 (66.67%)
No 19 (33.33%)
Unknown 2
Contraceptive method
COC 50 (84.75%)
PP 4 (6.78%)
Ring 1 (1.69%)
Patch 1 (1.69%)
DMPA 3 (5.08%)
Implant 0
IUD 0
COC = combined oral contraception; PP = progesterone-only pill; Ring
= vaginal ring; patch = transdermal patch; DMPA = depot medroxyprog-
esterone acetate; implant = subdermal etonorgestrel implant; IUD = in-
tra-uterine device Unknown factors were not included in the percent-
ages.
Total patients who answered
n = 145
Continuers
n = 106
Discontinuers
n = 39
p-value
Smoking 0.696
Yes 51 (35.17%) 36 (33.96%) 15 (38.46%)
No 94 (64.83%) 70 (66.04%) 24 (61.54%)
Legal representative informed 0.148
Yes 120 (86.96%) 93 (89.42%) 27 (79.41%)
No 18 (13.04%) 11 (10.58%) 7 (20.59%)
Unknown 7 2 5
COC = combined oral contraception; PP = progesterone-only pill; Ring = vaginal ring; patch = transdermal patch; DMPA = depot medroxyprogesterone acetate; implant = subder-
mal etonorgestrel implant; IUD = intra-uterine device Unknown factors were not included in the percentages.
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Another factor we studied was the impact of tobacco. In
our study, the answering and continuation rates of smokers
were comparable to those of nonsmokers. This contrasts
with the observations of Westhoff [17], who also studied
adolescents using COC and reported that smoking nega-
tively influenced adherence. A hypothesis to explain this
difference is that the percentage of smokers was only 18%
in their study versus 38% in ours, and that the smoking
population is probably different in the United States, given
the more negative image of tobacco in American society.
Regarding the thromboembolic risks of combined oestro-
gen-progestogens, and despite recent controversies, we
found COC to be the most frequently prescribed contracep-
tive method. Our selection criteria may explain why only a
small proportion of the patients in our study used IUD, as
they excluded adolescents already on contraception. More-
over, following current recommendations encouraging the
use of LARC in adolescents [25], it is likely that the pro-
portion of IUDs prescribed has grown since the start of our
study.
Another influencing factor studied was school dropouts,
since Maslyanskaya [23] found a link between these and
continuation rates. However, in our study, there were very
few school dropouts and adolescents in a professional en-
vironment did not have a different contraception continua-
tion rate from those enrolled in school or college.
Furthermore, the legal representative’s knowledge of con-
traceptive use did not influence participation in the study
nor contraception continuation. Unfortunately, this vari-
able is rarely reported in other studies.
Even though very few adolescents chose a patch or a ring
as contraception, continuation was very low, possibly due
to general misunderstanding of how to use these products
or their side effects. Similar results have been found previ-
ously [1, 9, 10, 15, 20, 21]. More evidence is needed. In the
meantime, medical professionals should be careful when
prescribing these methods to young patients.
The first reason given by our adolescent subjects to explain
interruption of contraception was the end of their romantic
and sexual relationship. Financial considerations certainly
increase this phenomenon in our country, as women bear
the costs of their contraception. This is not an issue when
a LARC method has been chosen and paid for at the be-
ginning. A particular feature of adolescents’ sexuality is
that it is frequently unpredictable, unplanned and associ-
ated with a feeling of invulnerability; that is why it is im-
portant that teenagers continue their contraception method
despite a short pause in sexual relations. One fifth of dis-
continuers were, in fact, subjects who changed contracep-
tive methods, illustrating their dissatisfaction regarding the
first prescribed method. This could impair compliance and
lead to contraceptive failure, particularly for non-LARC
methods.
Our study has some weaknesses. Firstly, we note the small
number of patients using methods other than COC, which
prevents reliable comparisons between different contracep-
tive methods or conclusions regarding the other methods.
Secondly, LARC methods were rarely prescribed. Howev-
er, our encouraging results regarding continuation and sat-
isfaction, in accordance with literature data, led our insti-
tution to suggest them increasingly to adolescents. Also,
many foreign patients were lost to follow-up, which could
have led to a bias regarding the statistical impact of nation-
ality on continuation rates. Lastly, another weakness and
possible bias is that the continuation rate was self-declared.
The main strength of our study is that it is the first prospec-
tive study on this topic in Switzerland. Also, we noted a
high answer rate 1 year after prescription. Moreover, the
lack of intervention or subvention is consistent with “real-
life” conditions, allowing a practical application of our re-
sults in effective contraception counselling.
This study underlines adolescents high adherence to con-
traception in Switzerland, which is not altered by confiden-
tiality. The results also underline the necessity of making
teenagers aware of the importance of continuing contra-
ception despite romantic breakups. The significant impact
of the type of contraceptive method on continuation rate
stresses the importance of individualised counselling for
young patients, even in a country where teen pregnancy is
low. Expanding the survey to other parts of Switzerland or
to other similar countries could bring more powerful re-
sults and give practitioners other interesting tools to help
individualized counselling.
This research has been presented at the 14th Congress /
2nd Global Conference of the European Society of Con-
traception and Reproductive Health, 4–7 May 2016, as a
poster; and at the Annual Congress of the Société Suisse
de Gynécologie-Obstétrique, 22–24 June 2016, as a poster
and an oral presentation.
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Appendix 1 Questionnaire
The questionnaire is available as a separate file at
https://smw.ch/en/article/doi/smw.2017.14504.
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